In 2019 when I first discussed exosomes for hair growth, most doctors were injecting them into the scalp. Recently, I also discussed the rarer intravenous (IV) delivery of exosomes to tackle hair loss. Now I look at the topical application of exosome serums into the scalp, due to three such new products being in recent news.
Note that some injectable products from exosome suppliers to the hair loss market can also be applied topically. The method of delivery will depend on your doctor’s or clinic’s preference.
Calecim (PTT-6) Advanced Hair System with Topical Exosomes
Last month, HairClone (UK) announced a partnership in which the company will work with an interesting new exosome containing topical product called Calecim Advanced Hair System (that comes with a Derma Stamp). Edit: The manufacturer has now given blog readers a 15% off discount code “HLC2020“.
This Calecim product includes PTT-6®, which contains over 3,000 proteins, including growth factors, cytokines and exosomes that signal cells to regenerate.
PTT-6 is derived from the secretion of cord lining stem cells isolated from the umbilical cord tissues of New Zealand red deer at birth. No deer is harmed during the extraction and harvest process of this rich source of stem cells.
The full list of ingredients is PTT-6® and cord lining conditioned media (from stem cell derived fibronectins, glycoproteins, albumin, collagens and hyaluronic acid).
This Calecim topical serum is to be used with an included Derma Stamp for better absorption. A lot people underetrake at-home microneedling for similar reasons. This includes via dermarollers or dermapens or dermastamps.
Elevai Exosomes Combined with Yuva Biosciences Mitochondrial Technology
Yesterday, reader “John Doe” posted a link to a positive update from Elevai Labs (US) regarding the company’s topical Elevai “age zero” Exosomes™ product range for hair loss. In a year-long study that the company conducted, patients who used Elevai empower™ exosomes in combination with in-office microneedling saw favorable results. The company also makes Elevai enfinity™ for at-home use in repairing your skin.
The 12-month results were assessed using imaging analysis and showed a cessation in crown inflammation, a reversal of miniaturized hairs, and a recovery of hairs from the dormant resting phase. the still on-going research study is being conducted in partnership with Carly Klein, president of the National Hair Loss Medical Aesthetics (NHLMA).
Note that I previously also discussed Elevai in my post on Yuva Biosciences and BosleyMDs new hair loss product related to mitochondrial upregulation. Yuva is partnering with Elevai to release a hair loss product that will combine Elevai’s proprietary PREx™ exosome technology with Yuva’s Y100™ mitochondrial technology. The two companies jointly filed for a combination patent in August 2024.
Ultimately, Elevai is developing a new hair and scalp care product line, called “Elevai S-Series Root Renewal System” that will be powered by exosomes and mitochondrial technology. According to company CEO Dr. Jordan R. Plews, they are in the process of conducting a follow-on study. This will further analyze the combination of Elevai exosomes and Yuva’s Y100 mitochondrial technology to address hair loss and thinning concerns.
ExoCelBio Evovex Serum
Another company that makes a line of topical exosomes is ExoCelBio (US) via its Evovex serum. The company website says that these exosomes are derived from the chorion of placental mesenchymal stem cells (pMSCs). Their Exovex™ serum Refine brand was launched in 2023 and has a concentration level of 75 billion exosomes per vial. Refine employs a high concentration of non-lyophilized, purified exosomes that results in fuller and stronger hair.
In May 2024, the US FDA sent a violation warning letter to ExoCelBio in relation to the company’s marketing and lack of a biologics license. This is not surprising, considering the new stricter FDA guidelines governing exosome products. In the US, exosomes are regulated as both a drug and a biologic. In Europe, you are not even allowed to use human-derived exosomes to treat hair loss.